AB 941: Controlled substances: psychedelic-assisted therapy.
- Session Year: 2023-2024
- House: Assembly
- Latest Version Date: 2024-01-04
Current Status:
Failed
(2024-07-01: In committee: Set, first hearing. Hearing canceled at the request of author.)
Introduced
In Committee
First Chamber
In Committee
Second Chamber
Enacted
Existing law, the California Uniform Controlled Substances Act, categorizes certain drugs and other substances as controlled substances and prohibits various actions related to those substances, including their manufacture, transportation, sale, possession, and use.
This bill would require the California Health and Human Services Agency to convene a workgroup to study and make recommendations on the establishment of a framework governing psychedelic-assisted therapy, as defined. The bill would require that workgroup to send a report to the Legislature containing those recommendations on or before January 1, 2026. The bill would, contingent upon the Legislature enacting a framework governing psychedelic-assisted therapy, authorize a facilitator in a licensed facility to administer specified controlled substances to combat veterans, as defined. authorize the lawful use of hallucinogenic or psychedelic substances for psychedelic-assisted therapy.
Existing law, the California Uniform Controlled Substances Act, categorizes certain drugs and other substances as controlled substances and prohibits various actions related to those substances, including their manufacture, transportation, sale, possession, and use.
This bill, the End Veteran Suicide Act, would authorize a licensed professional clinical counselor to administer controlled substances to combat veterans, as specified. The bill would require the psychedelic-assisted therapy to take place over a minimum of 30 sessions and would require a therapy session to be a minimum of 12 hours in duration, which may occur overnight, as necessary. The bill would also require 2 or 3 licensed professional clinical counselors to be present per patient at a psychedelic-assisted therapy session.This bill would require the California Health and Human Services Agency to convene a workgroup to study and make recommendations on the establishment of a framework governing psychedelic-assisted therapy, as defined. The bill would require that workgroup to send a report to the Legislature containing those recommendations on or before January 1, 2026. The bill would, contingent upon the Legislature enacting a framework governing psychedelic-assisted therapy, authorize a facilitator in a licensed facility to administer specified controlled substances to combat veterans, as defined.
Existing law, the California Uniform Controlled Substances Act, categorizes certain drugs and other substances as controlled substances and prohibits various actions related to those substances, including their manufacture, transportation, sale, possession, and use.
This bill, the End Veteran Suicide Act, would authorize a licensed professional clinical counselor to administer controlled substances to combat veterans, as specified. The bill would require the psychedelic-assisted therapy to take place over a minimum of 30 sessions and would require a therapy session to be a minimum of 12 hours in duration, which may occur overnight, as necessary. The bill would also require 2 or 3 licensed professional clinical counselors to be present per patient at a psychedelic-assisted therapy session.
Existing law, the California Uniform Controlled Substances Act, regulates the distribution and use of controlled substances, as defined. The act authorizes a hospital that does not employ a resident pharmacist to purchase controlled substances as specified to provide a supply of controlled substances necessary to handle emergency cases.This bill would make technical, nonsubstantive changes to these provisions.Existing law, the California Uniform Controlled Substances Act, regulates the distribution and use of controlled substances, as defined. The act authorizes a hospital that does not employ a resident pharmacist to purchase controlled substances as specified to provide a supply of controlled substances necessary to handle emergency cases.
This bill would make technical, nonsubstantive changes to these provisions.
The Legislature finds and declares all of the following:
(a)Clinical research demonstrates the potential use of some psychedelic compounds, in conjunction with therapy, for the treatment of mental health. Such as end-of-life anxiety, depression, post-traumatic stress disorder, and substance use disorders. These disorders are common in combat veterans.
(b)Measure 109 in Oregon, which passed in November 2020, with a 56-percent vote of the state population, will establish a regulated psilocybin therapy system in Oregon to provide people therapeutic access to psilocybin.
(c)The Oregon Psilocybin Services Section began accepting applications for licensure on January 2, 2023. Psilocybin service centers began to open their doors to clients in the summer of 2023. It takes time for all four license types (manufacturing, laboratory, service centers, and facilitators) to become licensed and set up operations. Each licensed service center, and the licensed facilitators who work with them, manage their own operations and communications with clients.
(d)This act will allow for the therapeutic use of specified controlled substances in a clinical setting for the purpose of individual healing, risk reduction, and other related services, but delays implementation of this provision until a framework for the therapeutic use is developed and adopted. This bill lays the groundwork for California to develop a therapeutic access program for psychedelic plants and fungi.
SEC. 2.Section 11214 is added to the Health and Safety Code, to read:11214.(a)The California Health and Human Services Agency shall convene a workgroup to study and make recommendations on the establishment of a framework governing psychedelic-assisted therapy using all of the following:
(1)Psilocybin.
(2)Ibogaine.
(3)Any controlled substance the federal Food and Drug Administration may approve for use in the future, including, but not limited to, Dimethyltryptamine or Mescaline sourced from nonpeyote cacti.
(b)The Secretary of California Health and Human Services or their designee shall be the chairperson of the workgroup.
(c)The workgroup shall include, but not be limited to, all of the following:
(1)Persons with expertise in psychedelic therapy, medicine, and public health, drug policy, harm reduction, and youth drug education.
(2)Law enforcement and emergency medical services or fire service first responders.
(3)People with experience with the traditional indigenous use of psychedelic substances, including representatives from the National Council of the Native American Church and Indian tribes in California.
(4)Veterans groups.
(5)University researchers with expertise in psychedelics.
(6)Research scientists with expertise in clinical studies and drug approval process under the federal Food and Drug Administration.
(7)Individuals from other states that have decriminalized psychedelics and established regulatory frameworks for the lawful use of psychedelics.
(d)The workgroup shall study subjects, including, but not limited to, all of the following:
(1)Research on the safety and efficacy of using each of the controlled substances specified in subdivision (a) in a therapeutic setting for treating post-traumatic stress disorder, depression, anxiety, addiction, and other mental health conditions.
(2)Long-term impact of supervised psychedelic or dissociative drug use with seeking and misusing other substances, including alcohol, cannabis, illicit substances, and unregulated psychedelic or dissociative drugs.
(3)Perceptions of harm of psychedelic or dissociative drugs following enactment of decriminalization both on a personal use and therapeutic use level.
(4)Impact of different regulatory frameworks on different health outcomes among vulnerable populations, including people with substance use disorders, and minority or disenfranchised groups.
(5)Regulated use models for the controlled substances specified in subdivision (a) from other jurisdictions.
(6)Content and scope of educational campaigns that have proven effective in accurate public health approaches regarding use, effect, and risk reduction for the substances specified in subdivision (a), including, but not limited to, public service announcements, educational curricula, appropriate crisis response, and appropriate training for first responders and multiresponders, including law enforcement, emergency medical services, fire service, and unarmed coresponder units.
(7)Policies for minimizing use-related risks, including information related to appropriate use and impacts of detrimental substance use.
(8)Appropriate frameworks to govern the therapeutic use of controlled substances, including qualifications and training for therapists or facilitators.
(e)The workgroup shall develop policy recommendations regarding, but not limited to, all of the following:
(1)Development of a statewide program or programs for the training of individuals providing psychedelic-assisted therapy.
(2)Development of a statewide credentialing process for individuals providing psychedelic-assisted therapy . therapy.
(3)The content and scope of educational campaigns and accurate public health approaches regarding use, effect, risk reduction, and safety for the substances specified in subdivision (a).
(4)Policies for minimizing use-related risks, including information related to appropriate use and impacts of detrimental substance use.
(5)Policies for the regulation of controlled substances specified in subdivision (a), including responsible marketing, product safety, and cultural responsibility.
(6)Policies for the safe and equitable production, access, use, and delivery of the controlled substances specified in subdivision (a).
(f)Subsequent to the Legislatures adoption of a framework governing psychedelic-assisted therapy using the substances described in subdivision (a), it is the intent of the Legislature that the transfer of a substance described in subdivision (a), without financial gain, in the context of psychedelic-assisted therapy, be decriminalized.
(g)As used in this section, psychedelic-assisted therapy means the supervised, lawful medical use by an individual 21 years of age or older of a controlled substance for treatment, including, but not limited to, group counseling and community-based healing, under the care of, administration by, and treatment of a licensed professional clinical counselor in a clinical setting.
(h)(1) On or before January 1, 2026, the workgroup shall submit a report to the Legislature detailing its findings and recommendations.
(2)A report to be submitted pursuant to this subdivision shall be submitted in compliance with Section 9795 of the Government Code.
(i)This section shall remain in effect until January 1, 2027, and as of that date is repealed.
SEC. 3.Article 5 (commencing with Section 11260) is added to Chapter 5 of Division 10 of the Health and Safety Code, to read:5.End Veteran Suicide Act Psychedelic-Assisted Therapy 11260.This act shall be known, and may be cited, as the End Veteran Suicide Act.11260.01.(a)Notwithstanding any other law, a facilitator in a licensed facility may administer the substances identified in this section as part of psychedelic-assisted therapy to treat a combat veteran who has a traumatic brain injury or who is suffering from post-traumatic stress disorder or addiction.11260.(a)Notwithstanding any other law, and upon the legislative enactment of a framework governing psychedelic-assisted therapy as recommended by the California Health and Human Services Agency workgroup pursuant to Section 11214, to include, but not be limited to, the list of substances to be used, the populations to be served, and the education, training, and licensure, if appropriate, required for those administering the substance, the use of hallucinogenic or psychedelic substances for psychedelic-assisted therapy shall be lawful.
(b)The scope of the psychedelic-assisted therapy may vary based on the treatment required and the injury or disorder being treated.
(c)All of the following substances may be used in psychedelic-assisted therapy pursuant to subdivision (a):(1)Psilocybin.(2)Ibogaine.(3)Any controlled substance the federal Food and Drug Administration may approve for use in the future, including, but not limited to, Dimethyltryptamine or Mescaline sourced from non-peyote cacti. (d)For purposes of this article, the following terms have the following meanings:(1)Combat veteran means a veteran of the Armed Forces of the United States who served in a combat role, which includes all special operations forces, and who is 21 years of age or older.(2)Psychedelic-assisted(c)For purposes of this article, psychedelic-assisted therapy includes the supervised, lawful medical use by an individual 21 years of age or older of a controlled substance for treatment, including, but not limited to, group counseling and community-based healing, under the care of, administration by, and treatment of a licensed professional clinical counselor in a clinical setting.
(e)(d)This article shall become operative only upon the Legislature enacting a framework for the governing of a psychedelic-assisted therapy.
The Legislature finds and declares all of the following:
(a)Clinical research demonstrates the potential use of some psychedelic compounds, in conjunction with therapy, for the treatment of mental health. Such as end-of-life anxiety, depression, post-traumatic stress disorder, and substance use disorders. These disorders are common in combat veterans.
(b)Measure 109 in Oregon, which passed in November 2020, with a 56-percent vote of the state population, will establish a regulated psilocybin therapy system in Oregon to provide people therapeutic access to psilocybin.
(c)The Oregon Psilocybin Services Section began accepting applications for licensure on January 2, 2023. Psilocybin service centers began to open their doors to clients in the summer of 2023. It takes time for all four license types (manufacturing, laboratory, service centers, and facilitators) to become licensed and set up operations. Each licensed service center, and the licensed facilitators who work with them, manage their own operations and communications with clients.
(d)This act will allow for the therapeutic use of specified controlled substances in a clinical setting for the purpose of individual healing, risk reduction, and other related services, but delays implementation of this provision until a framework for the therapeutic use is developed and adopted. This bill lays the groundwork for California to develop a therapeutic access program for psychedelic plants and fungi.
SEC. 2.Section 11214 is added to the Health and Safety Code, to read:11214.(a)The California Health and Human Services Agency shall convene a workgroup to study and make recommendations on the establishment of a framework governing psychedelic-assisted therapy using all of the following:
(1)Psilocybin.
(2)Ibogaine.
(3)Any controlled substance the federal Food and Drug Administration may approve for use in the future, including, but not limited to, Dimethyltryptamine or Mescaline sourced from nonpeyote cacti.
(b)The Secretary of California Health and Human Services or their designee shall be the chairperson of the workgroup.
(c)The workgroup shall include, but not be limited to, all of the following:
(1)Persons with expertise in psychedelic therapy, medicine, and public health, drug policy, harm reduction, and youth drug education.
(2)Law enforcement and emergency medical services or fire service first responders.
(3)People with experience with the traditional indigenous use of psychedelic substances, including representatives from the National Council of the Native American Church and Indian tribes in California.
(4)Veterans groups.
(5)University researchers with expertise in psychedelics.
(6)Research scientists with expertise in clinical studies and drug approval process under the federal Food and Drug Administration.
(7)Individuals from other states that have decriminalized psychedelics and established regulatory frameworks for the lawful use of psychedelics.
(d)The workgroup shall study subjects, including, but not limited to, all of the following:
(1)Research on the safety and efficacy of using each of the controlled substances specified in subdivision (a) in a therapeutic setting for treating post-traumatic stress disorder, depression, anxiety, addiction, and other mental health conditions.
(2)Long-term impact of supervised psychedelic or dissociative drug use with seeking and misusing other substances, including alcohol, cannabis, illicit substances, and unregulated psychedelic or dissociative drugs.
(3)Perceptions of harm of psychedelic or dissociative drugs following enactment of decriminalization both on a personal use and therapeutic use level.
(4)Impact of different regulatory frameworks on different health outcomes among vulnerable populations, including people with substance use disorders, and minority or disenfranchised groups.
(5)Regulated use models for the controlled substances specified in subdivision (a) from other jurisdictions.
(6)Content and scope of educational campaigns that have proven effective in accurate public health approaches regarding use, effect, and risk reduction for the substances specified in subdivision (a), including, but not limited to, public service announcements, educational curricula, appropriate crisis response, and appropriate training for first responders and multiresponders, including law enforcement, emergency medical services, fire service, and unarmed coresponder units.
(7)Policies for minimizing use-related risks, including information related to appropriate use and impacts of detrimental substance use.
(8)Appropriate frameworks to govern the therapeutic use of controlled substances, including qualifications and training for therapists or facilitators.
(e)The workgroup shall develop policy recommendations regarding, but not limited to, all of the following:
(1)Development of a statewide program or programs for the training of individuals providing psychedelic-assisted therapy.
(2)Development of a statewide credentialing process for individuals providing psychedelic-assisted therapy .
(3)The content and scope of educational campaigns and accurate public health approaches regarding use, effect, risk reduction, and safety for the substances specified in subdivision (a).
(4)Policies for minimizing use-related risks, including information related to appropriate use and impacts of detrimental substance use.
(5)Policies for the regulation of controlled substances specified in subdivision (a), including responsible marketing, product safety, and cultural responsibility.
(6)Policies for the safe and equitable production, access, use, and delivery of the controlled substances specified in subdivision (a).
(f)Subsequent to the Legislatures adoption of a framework governing psychedelic-assisted therapy using the substances described in subdivision (a), it is the intent of the Legislature that the transfer of a substance described in subdivision (a), without financial gain, in the context of psychedelic-assisted therapy, be decriminalized.
(g)As used in this section, psychedelic-assisted therapy means the supervised, lawful medical use by an individual 21 years of age or older of a controlled substance for treatment, including, but not limited to, group counseling and community-based healing, under the care of, administration by, and treatment of a licensed professional clinical counselor in a clinical setting.
(h)(1) On or before January 1, 2026, the workgroup shall submit a report to the Legislature detailing its findings and recommendations.
(2)A report to be submitted pursuant to this subdivision shall be submitted in compliance with Section 9795 of the Government Code.
(i)This section shall remain in effect until January 1, 2027, and as of that date is repealed.
SECTION 1.SEC. 3.Article 5 (commencing with Section 11260) is added to Chapter 5 of Division 10 of the Health and Safety Code, to read:5.End Veteran Suicide Act11260.This act shall be known, and may be cited, as the End Veteran Suicide Act.
11260.01.(a)A licensed professional clinical counselor may administer controlled substances Notwithstanding any other law, a facilitator in a licensed facility may administer the substances identified in this section as part of psychedelic-assisted therapy to treat a combat veteran who has a traumatic brain injury or who is suffering from post-traumatic stress disorder or addiction.
(b)(1)The scope of the psychedelic-assisted therapy may vary based on the treatment required and the injury or disorder being treated.
(2)The psychedelic-assisted therapy shall satisfy all of the following requirements:(A)The therapy shall take place over a minimum of 30 sessions, with the opportunity for additional sessions at the discretion of the licensed professional clinical counselor.(B)There shall be at least two, but no more than three, licensed professional clinical counselors present for each patient at a psychedelic-assisted therapy session.(C)A therapy session shall be a minimum of 12 hours in duration and may occur overnight, as necessary.(c)All of the following substances may be used in psychedelic-assisted therapy pursuant to subdivision (a):
(1)Psilocybin.
(2)Ibogaine.
(3)Any controlled substance the federal Food and Drug Administration may approve for use in the future, including, but not limited to, Dimethyltryptamine or Mescaline sourced from non-peyote cacti.
(c)(d)For purposes of this article, the following terms have the following meanings:
(1)Combat veteran means a veteran of the Armed Forces of the United States who served in a combat role, which includes all special operations forces. forces, and who is 21 years of age or older.
(2)Controlled substance includes any controlled substance the federal government may approve for use in the future, including, but not limited to, psilocybin, lysergic acid diethylamide (LSD), ketamine, 3,4-methylenedioxymethamphetamine (MDMA), and ibogaine.(3)(A)Licensed professional clinical counselor has the same meaning as defined in Article 1 (commencing with Section 4999.10) of Chapter 16 of Division 2 of the Business and Professions Code.(B)A licensed professional clinical counselor shall have a background in controlled substances in order to administer controlled substances under this article.(C)For purposes of this act, a licensed professional clinical counselor does not include a marriage therapist or a family therapist.(4)(2)Psychedelic-assisted therapy includes the supervised, lawful medical use by an individual 21 years of age or older of a controlled substance for treatment, including, but not limited to, group counseling and community-based healing, under the care of, administration by, and treatment of a licensed professional clinical counselor in a clinical setting.
(e)This article shall become operative only upon the Legislature enacting a framework for the governing of a psychedelic-assisted therapy.
This act shall be known, and may be cited, as the End Veteran Suicide Act.
11260.01.(a)A licensed professional clinical counselor may administer controlled substances as part of psychedelic-assisted therapy to treat a combat veteran who has a traumatic brain injury or who is suffering from post-traumatic stress disorder or addiction.
(b)(1)The scope of the psychedelic-assisted therapy may vary based on the treatment required and the injury or disorder being treated.
(2)The psychedelic-assisted therapy shall satisfy all of the following requirements:
(A)The therapy shall take place over a minimum of 30 sessions, with the opportunity for additional sessions at the discretion of the licensed professional clinical counselor.
(B)There shall be at least two, but no more than three, licensed professional clinical counselors present for each patient at a psychedelic-assisted therapy session.
(C)A therapy session shall be a minimum of 12 hours in duration and may occur overnight, as necessary.
(c)For purposes of this article, the following terms have the following meanings:
(1)Combat veteran means a veteran of the Armed Forces of the United States who served in a combat role, which includes all special operations forces.
(2)Controlled substance includes any controlled substance the federal government may approve for use in the future, including, but not limited to, psilocybin, lysergic acid diethylamide (LSD), ketamine, 3,4-methylenedioxymethamphetamine (MDMA), and ibogaine.
(3)(A)Licensed professional clinical counselor has the same meaning as defined in Article 1 (commencing with Section 4999.10) of Chapter 16 of Division 2 of the Business and Professions Code.
(B)A licensed professional clinical counselor shall have a background in controlled substances in order to administer controlled substances under this article.
(C)For purposes of this act, a licensed professional clinical counselor does not include a marriage therapist or a family therapist.
(4)Psychedelic-assisted therapy includes the supervised, lawful medical use of a controlled substance for treatment, including, but not limited to, group counseling and community-based healing, under the care of, administration by, and treatment of a licensed professional clinical counselor in a clinical setting.
SECTION 1.Section 11211 of the Health and Safety Code is amended to read:11211.In order to provide a supply of controlled substances necessary to handle emergency cases, a hospital that does not employ a resident pharmacist and that is under the supervision of a licensed physician, may purchase controlled substances on federal order forms for that institution, under the name of the hospital. The supply shall be made available to a registered nurse for administration to patients in emergency cases, upon direction of a licensed physician.In order to provide a supply of controlled substances as may be necessary to handle emergency cases, any a hospital which that does not employ a resident pharmacist and which that is under the supervision of a licensed physician, may purchase controlled substances on federal order forms for such that institution, under the name of such hospital, such the hospital. The supply to shall be made available to a registered nurse for administration to patients in emergency cases, upon direction of a licensed physician.
|
Date
|
Status
|
|---|---|
| Jul 1, 2024 | In committee: Set, first hearing. Hearing canceled at the request of author. |
| May 1, 2024 | Referred to Com. on HEALTH. |
| Jan 30, 2024 | In Senate. Read first time. To Com. on RLS. for assignment. |
| Jan 30, 2024 | Read third time. Passed. Ordered to the Senate. (Ayes 58. Noes 0. Page 3967.) |
| Jan 22, 2024 | Read second time. Ordered to third reading. |
| Jan 18, 2024 | From committee: Do pass. (Ayes 11. Noes 0.) (January 18). |
| Jan 18, 2024 | In committee: Set, first hearing. Referred to APPR. suspense file. |
| Jan 9, 2024 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 11. Noes 0.) (January 9). Re-referred to Com. on APPR. |
| Jan 8, 2024 | Re-referred to Com. on HEALTH. |
| Jan 4, 2024 | From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended. |
| Jan 4, 2024 | Re-referred to Com. on HEALTH. |
| Jan 3, 2024 | From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended. |
| Mar 28, 2023 | In committee: Set, first hearing. Hearing canceled at the request of author. |
| Mar 20, 2023 | Re-referred to Com. on HEALTH. |
| Mar 16, 2023 | From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended. |
| Mar 16, 2023 | Referred to Coms. on HEALTH and M. & V.A. |
| Feb 15, 2023 | From printer. May be heard in committee March 17. |
| Feb 14, 2023 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Jan 30, 2024 | AB 941 Waldron Assembly Third Reading | Assembly Floor |
Passed |
|
| Jan 18, 2024 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Jan 9, 2024 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
ASSEMBLY THIRD READING
ATR Bill Id:AB 941
Author:(Waldron)
As Amended Ver:January 4, 2024
Majority vote
SUMMARY
Requires the California Health and Human Services Agency (CHHSA) to convene a workgroup to study and make recommendations on the establishment of a framework governing psychedelic-assisted therapy, as defined. Requires the workgroup to send a report to the Legislature containing those recommendations on or before January 1, 2026. Makes, contingent upon the Legislature enacting a framework governing psychedelic-assisted therapy, the use of hallucinogenic/psychedelic substances for psychedelic-assisted therapy lawful.
Major Provisions
COMMENTS
- California and Federal Drug Schedules. California and Federal drug schedules closely mirror each other. Both have five schedules intended to list drugs in decreasing order of harm and increasing medical utility or safety and provides penalties for possession of and engaging in the commerce of controlled substances. Schedule I includes the most serious and heavily controlled substances, with Schedule V being the least serious and most lightly controlled substances.
- Hallucinogens. Hallucinogens are a diverse group of drugs that alter a person's perception or awareness of their surroundings. Some hallucinogens are found in plants and fungi and some are synthetically produced. According to the National Institute on Drug Abuse, hallucinogens are commonly split into two categories: classic hallucinogens and dissociative drugs. Both types can cause hallucinations, and dissociative drugs can cause the user to feel disconnected from their body or environment. Hallucinogens can be consumed in a variety of ways, including swallowed as tablets, pills, or liquid, consumed raw or dried, snorted, injected, inhaled, vaporized, smoked, or absorbed through the lining of the mouth using drug-soaked pieces of paper. Common hallucinogens include lysergic acid diethylamide (LSD), dimethyltryptamine (DMT), psilocybin, peyote, mescaline, and ketamine.
Many hallucinogenic substances, including LSD, DMT, mescaline, and psilocybin are classified as Schedule I substances under the state's Uniform Controlled Substances Act. Schedule I substances are defined as those controlled substances having no medical utility and that have a high potential for abuse. There is research, however, that indicates that many of these substances have therapeutic benefits. (Davis et. al, "Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder," JAMA Psychiatry (2020); D'Souza et al., "Exploratory Study of the Dose-Related Safety, Tolerability, and Efficacy of Dimethyltryptamine in Healthy Volunteers and Major Depressive Disorder, Neuropsychopharmacol" (2022); Köck et al., "A Systematic Literature Review of Clinical Trials and Therapeutic Applications of Ibogaine, Journal of Substance Abuse Treatment" (2022)).
In recent years, the federal Food and Drug Administration (FDA) has designated psilocybin as a "breakthrough therapy" to treat severe depression. (Saplakoglu, "FDA Calls Psychedelic Psilocybin a 'Breakthrough Therapy' for Severe Depression," Live Science (Nov. 25, 2019). The "breakthrough therapy" designation is "a process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint."
- Reform Efforts Related to Hallucinogens. Across the nation, local and statewide efforts to deprioritize the policing or prosecution of conduct related to certain hallucinogens and to acknowledge the therapeutic value of hallucinogens have gained support in recent years. In 2019, voters in Denver approved a measure to make the personal use and possession of psilocybin by adults 21 years of age and older the lowest law enforcement priority and to prohibit the city from spending resources to impose criminal penalties related to such conduct. That same year, the Oakland, California, City Council passed a resolution prohibiting the use of city funding "to assist in the enforcement of laws imposing criminal penalties for the use and possession of entheogenic plants by adults" and specifies that investigating people for growing, buying, distributing or possessing those substances "shall be amongst the lowest law enforcement priority for the City of Oakland." Similarly, a resolution passed by the Santa Cruz, California, City Council in 2020 made the personal possession and use of entheogenic plants and fungi a low priority for law enforcement.
In 2020, Oregon voters approved Measure 109, the Psilocybin Services Act, which directed the Oregon Health Authority to create a state-licensed, psilocybin-assisted therapy program over a two-year period. In implementing Measure 109, Oregon had to determine how to license and regulate the manufacturing, transportation, delivery, sale and purchase of psilocybin products as well as the provision of psilocybin services. Following the two-year development period for psilocybin services, the state began taking license applications on January 2, 2023. Psilocybin services refers to preparation, administration, and integration sessions provided by a licensed facilitator. Psilocybin services are available to individuals aged 21 and older and do not require a prescription or medical referral. The psilocybin products consumed must be cultivated or produced by a licensed psilocybin manufacturer and can only be provided to a client at a licensed psilocybin service center during an administration session. Psilocybin services are expected to be available to the public by early 2024.
- FDA Draft Guidance on Clinical Trials with Psychedelic Drugs. On June 23, 2023, FDA published a new draft guidance to highlight fundamental considerations to researchers investigating the use of psychedelic drugs for potential treatment of medical conditions, including for psychiatric conditions or substance use disorders (SUDs). This is the first FDA draft guidance that presents considerations to industry for designing clinical trials for psychedelic drugs.
There has been growing interest in the therapeutic potential of psychedelic drugs in recent years. They are being evaluated for use in the potential treatment of conditions such as depression, post-traumatic stress disorder, SUDs and other conditions. However, designing clinical studies to evaluate the safety and effectiveness of these compounds presents a number of unique challenges that require careful consideration.
According to Tiffany Farchione, M.D., director of the Division of Psychiatry in the FDA's Center for Drug Evaluation and Research, "Psychedelic drugs show initial promise as potential treatments for mood, anxiety and SUDs. However, these are still investigational products." Dr. Farchione further states that "sponsors evaluating the therapeutic potential of these drugs should consider their unique characteristics when designing clinical studies." By publishing this draft guidance, the FDA hopes to outline the challenges inherent in designing psychedelic drug development programs and provide information on how to address these challenges. The goal is to help researchers design studies that will yield interpretable results that will be capable of supporting future drug applications."
The purpose of the draft guidance is to advise researchers on study design and other considerations as they develop medications that contain psychedelics. Within the draft guidance, the term psychedelics refers to "classic psychedelics," typically understood to be drugs such as psilocybin and LSD that act on the brain's serotonin system, as well as "entactogens" or "empathogens" such as methylenedioxmethamphetamine.
The FDA draft guidance describes basic considerations throughout the drug development process including trial conduct, data collection, subject safety and new drug application requirements. For example, psychedelic drugs may produce psychoactive effects such as mood and cognitive changes, as well as hallucinations. As a result, there is the potential for abuse of these drugs, which is a drug safety issue that requires careful consideration and putting sufficient safety measures in place for preventing misuse throughout clinical development. For psychedelics that are currently Schedule I controlled substances, the draft guidance notes that activities associated with investigations under an Investigational New Drug Application must comply with applicable Drug Enforcement Administration regulatory requirements.
The evidentiary standard for establishing effectiveness of psychedelic drugs is the same as for all other drugs. However, there are unique factors investigators may need to consider when designing their clinical trials if those trials are to be considered adequate and well-controlled. The draft guidance also addresses the role of psychotherapy in psychedelic drug development, considerations for safety monitoring and the importance of characterizing dose-response and the durability of any treatment effect.
- Criminal under Federal Law. State authorization does not nullify federal drug laws, and the substances included in this bill remain illegal under federal law. As a result, state authorization for personal possession or for facilities providing "facilitated and supported use" of mescaline, DMT, Ibogaine, psilocybin, and psilocin would not prevent the federal government from shutting down those facilities. Likewise, state authorization does not provide immunity from federal criminal proceedings, if federal law enforcement was inclined to pursue them.
- For example, federal law provides, "It shall be unlawful for any person knowingly or intentionally to possess a controlled substance unless such substance was obtained directly, or pursuant to a valid prescription or order, from a practitioner, while acting in the course of his professional practice," or as otherwise specified. As noted in existing law above, federal law also makes it unlawful to do either of the following:
knowingly open, lease, rent, use, or maintain any place, whether permanently or temporarily, for the purpose of manufacturing, distributing, or using any controlled substance; or, - Manage or control any place, whether permanently or temporarily, either as an owner, lessee, agent, employee, occupant, or mortgagee, and knowingly and intentionally rent, lease, profit from, or make available for use, with or without compensation, the place for the purpose of unlawfully manufacturing, storing, distributing, or using a controlled substance.
- For example, federal law provides, "It shall be unlawful for any person knowingly or intentionally to possess a controlled substance unless such substance was obtained directly, or pursuant to a valid prescription or order, from a practitioner, while acting in the course of his professional practice," or as otherwise specified. As noted in existing law above, federal law also makes it unlawful to do either of the following:
It should be noted that provisions of this bill decriminalizing personal possession of specified hallucinogens and creating a pathway for their facilitated and supported use would still be considered unlawful under federal law.
According to the Author
Allowing for the controlled, therapeutic use of psychedelics for those with mental health disorders has the potential to save countless lives. By studying the best possible way to begin administering these treatments, we can protect the most vulnerable Californians who are suffering every day.
Arguments in Support
There is no known support for this bill.
Arguments in Opposition
There is no known opposition to this bill.
FISCAL COMMENTS
According to the Assembly Appropriations Committee, the California Health and Human Services Agency (CalHHSA) indicates it would likely delegate the required activities under this bill to the California Department of Public Health (DPH) and the Department of Health Care Services (DHCS) would participate as part of the workgroup, with the State Public Health Officer as chair. DPH estimates total costs of $1,550,000 (General Fund), as follows: $620,000 in each fiscal year (FY) 2024-25 and FY 2025-26, and $310,000 in FY 2026-27. Costs would support four full-time equivalent (FTE), limited-term program staff and one FTE, limited-term medical consultant to support meeting planning, facilitation, implementation, and report development. In addition, CalHHSA estimates one-time costs to DHCS of $309,000 to support one FTE, limited-term program analyst (General Fund).
VOTES
ASM HEALTH: 11-0-5
YES: Bonta, Waldron, Aguiar-Curry, Arambula, Wendy Carrillo, Flora, Haney, Jones-Sawyer, McCarty, Santiago, Schiavo
ABS, ABST OR NV: Vince Fong, Maienschein, Joe Patterson, Rodriguez, Weber
ASM APPROPRIATIONS: 11-0-5
YES: Holden, Arambula, Wood, Connolly, Mike Fong, Grayson, Haney, Hart, Lowenthal, Pellerin, Villapudua
ABS, ABST OR NV: Sanchez, Calderon, Megan Dahle, Dixon, Ta
UPDATED
VERSION: January 4, 2024
CONSULTANT: Lara Flynn / HEALTH / (916) 319-2097 FN: 0002592
Date of Hearing: January 18, 2024
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Chris Holden, Chair
ABPCA Bill Id:AB 941
Author:(Waldron) – As Amended Ver:January 4, 2024
Policy Committee: | Health | Vote: | 11 - 0 |
|
| ||
|
|
Urgency: No State Mandated Local Program: No Reimbursable: No
SUMMARY:
This bill requires the California Health and Human Services Agency (CalHHS) to convene a workgroup to make recommendations on a framework governing psychedelic-assisted therapy, and, contingent upon further legislation, authorizes the lawful use of hallucinogenic or psychedelic substances for therapy.
Specifically, this bill:
- Requires CalHHS to convene a workgroup to make recommendations on a framework governing psychedelic-assisted therapy using psilocybin, ibogaine, or any controlled substance the federal Food and Drug Administration (FDA) approves for use in the future (“psychedelics”).
- Requires the Secretary of CalHHS or their designee to chair the workgroup, and specifies other required members of the workgroup.
- Requires the workgroup to study specified aspects of therapeutic use of psychedelics, including safety and efficacy for treating post-traumatic stress disorder and other mental health conditions; long-term effects with respect to use of other substances; effects of regulatory frameworks on vulnerable populations; and other specified topics.
- Requires the workgroup to develop policy recommendations regarding the following with respect to therapeutic use of psychedelics: training of individuals providing services; development of a statewide credentialing process; education regarding use and safety; policies for minimizing risks; and the regulation and safe and equitable production, access, use, and delivery of psychedelics.
- Declares that subsequent to the Legislature’s adoption of a framework governing therapeutic use of psychedelics, the transfer of a psychedelic, without financial gain, in the context of psychedelic-assisted therapy, will be lawful.
FISCAL EFFECT:
CalHHS indicates it would likely delegate the required activities under this bill to the California Department of Public Health (CDPH) and the Department of Health Care Services (DHCS) would participate as part of the workgroup, with the State Public Health Officer as chair. CDPH estimates total costs of $1,550,000 (General Fund), as follows: $620,000 in each fiscal year (FY) 2024-25 and FY 2025-26, and $310,000 in FY 2026-27. Costs would support four full-time equivalent (FTE), limited-term program staff and one FTE, limited-term medical consultant to support meeting planning, facilitation, implementation, and report development.
In addition, CalHHS estimates one-time costs to DHCS of $309,000 to support one FTE, limited-term program analyst (General Fund).
COMMENTS:
- Purpose. According to the author:
Allowing for the controlled, therapeutic use of psychedelics for those with mental health disorders has the potential to save countless lives. By studying the best possible way to begin administering these treatments, we can protect the most vulnerable Californians who are suffering every day.
- Hallucinogens. Hallucinogens, including psychedelics, are a diverse group of drugs that alter perception or awareness of one’s surroundings. Some hallucinogens are found in plants and fungi and some are synthetically produced. Many hallucinogenic substances are classified as Schedule I substances under the state’s Uniform Controlled Substances Act. Schedule I substances are defined as those controlled substances having no medical utility and that have a high potential for abuse. Recent research indicates, however, that that many of these substances have therapeutic benefits. In 2019, FDA designated psilocybin as a “breakthrough therapy” to treat severe depression. The “breakthrough therapy” designation is intended to expedite the development and review of drugs to treat a serious condition when preliminary clinical evidence indicates the drug may demonstrate substantial improvement over available therapy.
- Prior Legislation.
SB 58 (Weiner), of the 2023-23 Legislative Session, would have decriminalized the use of specified hallucinogens for personal use, created the workgroup as delineated in this bill and, upon enactment of a framework, authorized the use of psychedelics for therapeutic treatment. Governor Newsom vetoed SB 58, stating, in part:
I urge the legislature to send me legislation next year that includes therapeutic guidelines. I am, additionally, committed to working with the legislature and sponsors of this bill to craft legislation that would authorize permissible uses and consider a framework for potential broader decriminalization in the future, once the impacts, dosing, best practice, and safety guardrails are thoroughly contemplated and put in place.
SB 519 (Wiener), of the 2021-22 Legislative Session, was substantially similar to SB 58 and died on the Assembly inactive file.
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
Date of Hearing: January 9, 2024
ASSEMBLY COMMITTEE ON HEALTH
Mia Bonta, Chair
ABPCA Bill Id:AB 941
Author:((Waldron) – As Amended Ver:January 4, 2024
SUBJECT: Controlled substances: psychedelic-assisted therapy.
SUMMARY: Requires the California Health and Human Services Agency (CHHSA) to convene a workgroup to study and make recommendations on the establishment of a framework governing psychedelic-assisted therapy, as defined. Requires the workgroup to send a report to the Legislature containing those recommendations on or before January 1, 2026. Makes, contingent upon the Legislature enacting a framework governing psychedelic-assisted therapy, the use of hallucinogenic/psychedelic substances for psychedelic-assisted therapy lawful. Specifically, this bill:
- Requires CHHSA to convene a workgroup to study and make recommendations on the establishment of a framework governing psychedelic-assisted therapy using all of the following:
- Psilocybin;
- Ibogaine; and,
- Any controlled substance the federal Food and Drug Administration (FDA) may approve for use in the future, including, but not limited to Dimethyltryptamine (DMT) or Mescaline sourced from nonpeyote cacti.
- Requires the Secretary of CHHSA, or their designee, to serve as the chairperson of the workgroup and requires that workgroup to also include, but not be limited to, all of the following:
- Persons with expertise in psychedelic therapy, medicine and public health, drug policy, harm reduction, and youth drug education;
- Law enforcement and emergency medical services or fire service first responders;
- People with experience with the traditional indigenous use of psychedelic substances, including representatives from the National Council of the Native American Church and Indian tribes in California;
- Veterans groups;
- University researchers with expertise in psychedelics;
- Research scientists with expertise in clinical studies and drug approval process under the FDA; and,
- Individuals from other states that have decriminalized psychedelics and established regulatory frameworks for the lawful use of psychedelics.
- Requires the workgroup to study subjects, including, but not limited to, all of the following:
- Research on the safety and efficacy of using each of the controlled substances identified in 1) above in a therapeutic setting for treating post-traumatic stress disorder (PTSD), depression, anxiety, addiction, and other mental health conditions;
- Long-term impacts of supervised psychedelic or dissociative drug use with seeking and misusing other substances, including alcohol, cannabis, illicit substances, and unregulated psychedelic or dissociative drugs;
- Perceptions of harm of psychedelic or dissociative drugs following enactment of decriminalization both on a personal use and therapeutic use level;
- Impacts of different regulatory frameworks on different health outcomes among vulnerable populations, including youth, people with substance use disorders (SUDs), and minority or disenfranchised groups;
- Regulated use models for the controlled substances specified in 1) above from other jurisdictions;
- Content and scope of educational campaigns that have proven effective in accurate public health approaches regarding use, effect, and risk reduction for the substances specified in 1) above, including, but not limited to, public service announcements, educational curricula, appropriate crisis response, and appropriate training for first responders and multi-responders, including law enforcement, emergency medical services, fire service, and unarmed co-responder units;
- Policies for minimizing use-related risks, including information related to appropriate use and impacts of detrimental substance use; and,
- Appropriate frameworks to govern the therapeutic use of controlled substances, including qualifications and training for therapists or facilitators.
- Requires the workgroup to develop policy recommendations regarding, but not limited to, all of the following:
- Development of a statewide program or programs for the training of individuals providing therapeutic psychedelic services in therapeutic settings, including facilitated and supported use settings;
- Development of a statewide credentialing process for individuals providing therapeutic psychedelic services in therapeutic settings, including facilitated or supported use settings;
- The content and scope of educational campaigns and accurate public health approaches regarding use, effect, risk reduction, and safety for the substances specified in 1) above;
- Policies for minimizing use-related risks, including information related to appropriate use and impacts of detrimental substance use;
- Policies for the regulation of controlled substances specified in 1) above, including responsible marketing, product safety, and cultural responsibility; and,
- Policies for the safe and equitable production, access, use, and delivery of the controlled substances specified in 1) above.
- Provides that subsequent to the Legislature’s adoption of a framework governing therapeutic use of the substances described in 1) above, it is the intent of the Legislature that the transfer of a substance described in 1) above, without financial gain, in the context of psychedelic-assisted therapy, be decriminalized.
- Defines “psychedelic-assisted therapy” to be the supervised, lawful medical use of a controlled substance for treatment, including but not limited to group counseling and community-based healing, under the care of, administration by, and treatment of a licensed professional in a clinical setting.
- Requires the workgroup to submit a report to the Legislature detailing its findings and recommendations on or before January 1, 2026.
- Repeals the study provisions of this bill effective January 1, 2027.
- Provides that notwithstanding any other law, and upon the Legislative enactment of a framework governing psychedelic-assisted therapy, the use of hallucinogenic/psychedelic substances for psychedelic-assisted therapy is lawful.
- Provides that the scope of the psychedelic-assisted therapy may vary based on the treatment required and injury or disorder being treated.
- Provides that 9) and 10) above are contingent upon the Legislature enacting a framework for the governing of psychedelic-assisted therapy.
- Finds and declares that clinical research demonstrates the potential use of some psychedelic compounds, in conjunction with therapy, for the treatment of mental health, such as end-of-life anxiety, depression, PTSD, and SUDs.
EXISTING FEDERAL LAW:
- Makes it unlawful for any person to knowingly or intentionally possess a controlled substance unless such substance was obtained directly, or pursuant to a valid prescription or order, from a practitioner, while acting in the course of their professional practice, or as otherwise specified. [21 United States Code (U.S.C.) § 844]
- Makes it unlawful to knowingly open, lease, rent, use, or maintain any place, whether permanently or temporarily, for the purpose of manufacturing, distributing, or using any controlled substance. [21 U.S.C. § 856 (a)]
- Makes it unlawful to manage or control any place, whether permanently or temporarily, either as an owner, lessee, agent, employee, occupant, or mortgagee, and knowingly and intentionally renting, leasing, profiting from, or making available for use, with or without compensation, for the purpose of unlawfully manufacturing, storing, distributing, or using a controlled substance. [21 U.S.C. § 856, (b)]
EXISTING STATE LAW:
- Lists controlled substances into five “schedules” intended to list drugs in decreasing order of harm and increasing medical utility or safety and provides penalties for the possession of and the engagement in commerce of a controlled substances. Includes in Schedule I the most serious and heavily controlled substances, with Schedule V being the least serious and most lightly controlled substances. [Health and Safety Code (HSC) § 11054-11058]
- Classifies several hallucinogenic substances including DMT, Ibogaine, mescaline, psilocybin, and psilocyn as Schedule I substances. [HSC § 11054(d)]
- Provides that, upon change in federal law permitting the prescription, furnishing, or dispensing of a cannabidiol product, a physician, pharmacist, or other authorized healing arts licensee acting within their scope of practice who prescribes, furnishes, or dispenses a cannabidiol product in accordance with federal law, is deemed to be in compliance with state law. [HSC §11150.2(a)]
- Prohibits the possession of numerous specified controlled substances. [HSC §11350(a)]
- Makes it is unlawful to possess any device, instrument, or paraphernalia used for unlawfully injecting or smoking specified controlled substances, except as specified. [HSC §11364(a)]
- Makes it unlawful for any person to deliver, furnish, or transfer, possess with intent to deliver, furnish, or transfer, or manufacture with the intent to deliver, furnish, or transfer, drug paraphernalia, knowing that it will be used to plant, propagate, cultivate, grow, harvest, compound, convert, produce, process, prepare, test, analyze, pack, repack, store, contain, conceal, inject, ingest, inhale, or otherwise introduce into the human body a controlled substance. [HSC §11364.7]
- Makes it unlawful to visit or to be in any room or place where specified controlled substances are being unlawfully smoked or used with knowledge that such activity is occurring. [HSC §11365(a)]
- Provides that the possession of methamphetamine and other specified controlled substances is unlawful. [HSC §11377(a)]
- Makes it unlawful for a person to transport, import into this state, sell, furnish, administer, or give away, or offer to transport, import into this state, sell, furnish, administer, or give away, or attempt to import into this state or transport specified controlled substances. [HSC § 11379]
- Makes it unlawful for a person to agree, consent, or in any manner offer to unlawfully sell, furnish, transport, administer, or give specified controlled substances.[HSC §11382]
- Provides that it is unlawful to be under the influence of specified controlled substances. [HSC §11550(a)]
- Makes it unlawful for a person who, with the intent to produce psilocybin or psilocyn, cultivates any spores or mycelium capable of producing mushrooms or other material which contains such a controlled substance. [HSC §11390]
- Makes it unlawful to transport, import into this state, sell, furnish, give away, or offer to transport, import into this state, sell, furnish, or give away any spores or mycelium capable of producing mushrooms or other material which contain psilocybin or psilocyn. [HSC §
11391]
FISCAL EFFECT: This bill has not yet been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, allowing for the controlled, therapeutic use of psychedelics for those with mental health disorders has the potential to save countless lives. By studying the best possible way to begin administering these treatments, we can protect the most vulnerable Californians who are suffering every day.
- BACKGROUND.
- California and Federal Drug Schedules. California and Federal drug schedules closely mirror each other. Both have five schedules intended to list drugs in decreasing order of harm and increasing medical utility or safety and provides penalties for possession of and engaging in the commerce of controlled substances. Schedule I includes the most serious and heavily controlled substances, with Schedule V being the least serious and most lightly controlled substances. The drugs on each schedule are largely consistent.
Schedule I – The drug has a high potential for abuse; the drug has no currently accepted medical use in treatment in the United States (U.S.); there is a lack of accepted safety for use of the drug under medical supervision.
Schedule II – The drug has a high potential for abuse; the drug has a currently accepted medical use in treatment in the U.S. or a currently accepted medical use with severe restrictions; abuse of the drug may lead to severe psychological or physical dependence.
Schedule III – The drug has potential for abuse less than the drugs or other substances in Schedule I and II; the drug has a currently accepted medical use in treatment in the U.S.; abuse of the drug or other substance may lead to moderate or low physical dependence or high psychological dependence.
Schedule IV – The drug has a low potential for abuse relative to the drugs in Schedule III; the drug has a currently accepted medical use in the U.S.; abuse of the drug may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in Schedule III.
Schedule V – The drug has a low potential for abuse relative to the drugs or other substances in IV; the drug has a currently accepted medical use in treatment in the U.S.; abuse of the drug may lead to limited physical dependence of psychological dependence relative to the drugs or other substances in Schedule IV. - Hallucinogens. Hallucinogens are a diverse group of drugs that alter a person’s perception or awareness of their surroundings. Some hallucinogens are found in plants and fungi and some are synthetically produced. According to the National Institute on Drug Abuse, hallucinogens are commonly split into two categories: classic hallucinogens and dissociative drugs. Both types can cause hallucinations, and dissociative drugs can cause the user to feel disconnected from their body or environment. Hallucinogens can be consumed in a variety of ways, including swallowed as tablets, pills, or liquid, consumed raw or dried, snorted, injected, inhaled, vaporized, smoked, or absorbed through the lining of the mouth using drug-soaked pieces of paper. Common hallucinogens include lysergic acid diethylamide (LSD), DMT, psilocybin, peyote, mescaline, and ketamine.
- California and Federal Drug Schedules. California and Federal drug schedules closely mirror each other. Both have five schedules intended to list drugs in decreasing order of harm and increasing medical utility or safety and provides penalties for possession of and engaging in the commerce of controlled substances. Schedule I includes the most serious and heavily controlled substances, with Schedule V being the least serious and most lightly controlled substances. The drugs on each schedule are largely consistent.
Many hallucinogenic substances, including LSD, DMT, mescaline, and psilocybin are classified as Schedule I substances under the state’s Uniform Controlled Substances Act. Schedule I substances are defined as those controlled substances having no medical utility and that have a high potential for abuse. There is research, however, that indicates that many of these substances have therapeutic benefits. (Davis et. al, “Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder,” JAMA Psychiatry (2020); D’Souza et al., “Exploratory Study of the Dose-Related Safety, Tolerability, and Efficacy of Dimethyltryptamine (DMT) in Healthy Volunteers and Major Depressive Disorder, Neuropsychopharmacol” (2022); Köck et al., “A Systematic Literature Review of Clinical Trials and Therapeutic Applications of Ibogaine, Journal of Substance Abuse Treatment” (2022)).
In recent years, the FDA has designated psilocybin as a “breakthrough therapy” to treat severe depression. (Saplakoglu, “FDA Calls Psychedelic Psilocybin a ‘Breakthrough Therapy’ for Severe Depression,” Live Science (Nov. 25, 2019). The “breakthrough therapy” designation is “a process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint.”
While research on hallucinogenic substances is promising, their use is not without risk. Hallucinogens included in this bill are associated with significant harms. The absence of adequate reporting systems to track these harms hampers the ability to quantify them, however, a review of the medical literature, demonstrates these drugs contribute to non-trivial risks for individuals and the public health. Case reports document adverse effects of psilocybin and other hallucinogens including acute panic (Nordic Council of Ministries, 2009; Riley and Blackman, 2008; van Amsterdam et al., 2011), risk of physical self-harm (Allen et al., 1991; Schwartz and Smith, 1988; van Amsterdam et al., 2011), self-harm resulting in death, including in cases with no known medical or psychiatric history (Honyiglo et al., 2019), medical help-seeking (Allen et al., 1991; Nordic Council of Ministries, 2009; Mowry et al., 2014), and enduring negative psychological or psychiatric problems (Allen et al., 1991; Nordic Council of Ministries, 2009; Nielen et al., 2004; Espiard et al., 2020; Hendin et al., 2021).
- Reform Efforts Related to Hallucinogens. Across the nation, local and statewide efforts to deprioritize the policing or prosecution of conduct related to certain hallucinogens and to acknowledge the therapeutic value of hallucinogens have gained support in recent years. In 2019, voters in Denver approved a measure to make the personal use and possession of psilocybin by adults 21 years of age and older the lowest law enforcement priority and to prohibit the city from spending resources to impose criminal penalties related to such conduct. That same year, the Oakland, California, City Council passed a resolution prohibiting the use of city funding “to assist in the enforcement of laws imposing criminal penalties for the use and possession of entheogenic plants by adults” and specifies that investigating people for growing, buying, distributing or possessing those substances “shall be amongst the lowest law enforcement priority for the City of Oakland.” Similarly, a resolution passed by the Santa Cruz, California, City Council in 2020 made the personal possession and use of entheogenic plants and fungi a low priority for law enforcement. The Ann Arbor, Michigan, City Council passed a similar measure that same year. Initiative 81, the Entheogenic Plant and Fungus Policy Act of 2020, makes “the investigation and arrest of persons 18 years of age or older, for non-commercial planting, cultivating, purchasing, transporting, distributing, engaging in practices with, and/or possessing entheogenic plants and fungi” among the lowest enforcement priorities for Washington D.C.’s local police department. Additional jurisdictions have passed similar measures since 2020.
In 2020, Oregon voters approved Measure 109, the Psilocybin Services Act, which directed the Oregon Health Authority to create a state-licensed, psilocybin-assisted therapy program over a two-year period. In implementing Measure 109, Oregon had to determine how to license and regulate the manufacturing, transportation, delivery, sale and purchase of psilocybin products as well as the provision of psilocybin services. Following the two-year development period for psilocybin services, the state began taking license applications on January 2, 2023. Psilocybin services refers to preparation, administration, and integration sessions provided by a licensed facilitator. Psilocybin services are available to individuals aged 21 and older and do not require a prescription or medical referral. The psilocybin products consumed must be cultivated or produced by a licensed psilocybin manufacturer and can only be provided to a client at a licensed psilocybin service center during an administration session. Psilocybin services are expected to be available to the public by early 2024.
More recently, Colorado voters approved Proposition 122 which, among things, decriminalized the personal possession and use of psilocybin, psilocyn, DMT, Ibogaine and mescaline for adults aged 21 and older. The measure additionally establishes a program for licensed “healing centers” to administer psilocybin and psilocyn to adults by licensed professionals, and creates a regulatory framework for the manufacture, cultivation, testing, storage, transport, transfer, delivery, sale, and purchase of the covered substances between healing centers and other permitted entities.
In 2021, Texas adopted House Bill 1802, which directed their Department of State Health Services to, in collaboration with the Texas Medical Board, conduct a study to evaluate the therapeutic efficacy of alternative therapies, including the use of 3, 4-methylenedioxmethamphetamine (MDMA), psilocybin, and ketamine in the treatment of mental health and other medical conditions including, depression, anxiety, PTSD; bipolar disorder; chronic pain and migraines. The evaluation is to include a determination of whether alternative therapies are effective in treating the mental health and other medical conditions described in the bill and to compare the efficacy of the alternative therapies with the efficacy of treatments currently used for those conditions.
- FDA Draft Guidance on Clinical Trials with Psychedelic Drugs. On June 23, 2023, FDA published a new draft guidance to highlight fundamental considerations to researchers investigating the use of psychedelic drugs for potential treatment of medical conditions, including for psychiatric conditions or SUDs. This is the first FDA draft guidance that presents considerations to industry for designing clinical trials for psychedelic drugs.
There has been growing interest in the therapeutic potential of psychedelic drugs in recent years. They are being evaluated for use in the potential treatment of conditions such as depression, PTSD, SUDs and other conditions. However, designing clinical studies to evaluate the safety and effectiveness of these compounds presents a number of unique challenges that require careful consideration.
According to Tiffany Farchione, M.D., director of the Division of Psychiatry in the FDA’s Center for Drug Evaluation and Research, “Psychedelic drugs show initial promise as potential treatments for mood, anxiety and SUDs. However, these are still investigational products.” Dr. Farchione further states that “sponsors evaluating the therapeutic potential of these drugs should consider their unique characteristics when designing clinical studies.” By publishing this draft guidance, the FDA hopes to outline the challenges inherent in designing psychedelic drug development programs and provide information on how to address these challenges. The goal is to help researchers design studies that will yield interpretable results that will be capable of supporting future drug applications.”
The purpose of the draft guidance is to advise researchers on study design and other considerations as they develop medications that contain psychedelics. Within the draft guidance, the term psychedelics refers to “classic psychedelics,” typically understood to be drugs such as psilocybin and LSD that act on the brain’s serotonin system, as well as “entactogens” or “empathogens” such as MDMA.
The FDA draft guidance describes basic considerations throughout the drug development process including trial conduct, data collection, subject safety and new drug application requirements. For example, psychedelic drugs may produce psychoactive effects such as mood and cognitive changes, as well as hallucinations. As a result, there is the potential for abuse of these drugs, which is a drug safety issue that requires careful consideration and putting sufficient safety measures in place for preventing misuse throughout clinical development. For psychedelics that are currently Schedule I controlled substances, the draft guidance notes that activities associated with investigations under an Investigational New Drug Application must comply with applicable Drug Enforcement Administration regulatory requirements.
The evidentiary standard for establishing effectiveness of psychedelic drugs is the same as for all other drugs. However, there are unique factors investigators may need to consider when designing their clinical trials if those trials are to be considered adequate and well-controlled. The draft guidance also addresses the role of psychotherapy in psychedelic drug development, considerations for safety monitoring and the importance of characterizing dose-response and the durability of any treatment effect.
- Criminal Under Federal Law. State authorization does not nullify federal drug laws, and the substances included in this bill remain illegal under federal law. As a result, state authorization for personal possession or for facilities providing “facilitated and supported use” of mescaline, DMT, Ibogaine, psilocybin, and psilocin would not prevent the federal government from shutting down those facilities. Likewise, state authorization does not provide immunity from federal criminal proceedings, if federal law enforcement was inclined to pursue them.
- For example, federal law provides, “It shall be unlawful for any person knowingly or intentionally to possess a controlled substance unless such substance was obtained directly, or pursuant to a valid prescription or order, from a practitioner, while acting in the course of his professional practice,” or as otherwise specified. As noted in existing law above, federal law also makes it unlawful to do either of the following:
Knowingly open, lease, rent, use, or maintain any place, whether permanently or temporarily, for the purpose of manufacturing, distributing, or using any controlled substance; or, - Manage or control any place, whether permanently or temporarily, either as an owner, lessee, agent, employee, occupant, or mortgagee, and knowingly and intentionally rent, lease, profit from, or make available for use, with or without compensation, the place for the purpose of unlawfully manufacturing, storing, distributing, or using a controlled substance.
- For example, federal law provides, “It shall be unlawful for any person knowingly or intentionally to possess a controlled substance unless such substance was obtained directly, or pursuant to a valid prescription or order, from a practitioner, while acting in the course of his professional practice,” or as otherwise specified. As noted in existing law above, federal law also makes it unlawful to do either of the following:
- Criminal Under Federal Law. State authorization does not nullify federal drug laws, and the substances included in this bill remain illegal under federal law. As a result, state authorization for personal possession or for facilities providing “facilitated and supported use” of mescaline, DMT, Ibogaine, psilocybin, and psilocin would not prevent the federal government from shutting down those facilities. Likewise, state authorization does not provide immunity from federal criminal proceedings, if federal law enforcement was inclined to pursue them.
It should be noted that provisions of this bill decriminalizing personal possession of specified hallucinogens and creating a pathway for their facilitated and supported use would still be considered unlawful under federal law.
- PREVIOUS LEGISLATION.
- SB 58 (Weiner) of 2023 would have decriminalized for personal use, the use of specified hallucinogenics by individuals 21 years of age or older, created the workgroup as delineated in this bill and upon enactment of a framework for psychedelic-assisted treatment authorized the use of psychedelics for therapeutic treatment. SB 58 was vetoed by Governor Newsom with the following veto statement:
“Both peer-reviewed science and powerful personal anecdotes lead me to support new opportunities to address mental health through psychedelic medicines like those addressed in this bill. Psychedelics have proven to relieve people suffering from certain conditions such as depression, PTSD, traumatic brain injury, and other addictive personality traits. This is an exciting frontier and California will be on the front-end of leading it. California should immediately begin work to set up regulated treatment guidelines - replete with dosing information, therapeutic guidelines, rules to prevent against exploitation during guided treatments, and medical clearance of no underlying psychoses. Unfortunately, this bill would decriminalize possession prior to these guidelines going into place, and I cannot sign it. I urge the legislature to send me legislation next year that includes therapeutic guidelines. I am, additionally, committed to working with the legislature and sponsors of this bill to craft legislation that would authorize permissible uses and consider a framework for potential broader decriminalization in the future, once the impacts, dosing, best practice, and safety guardrails are thoroughly contemplated and put in place.”
- SB 250 (Umberg), Chapter 106, Statutes of 2023, provides that a person is immune from prosecution for possession of a controlled substance or controlled substance analog for personal use if they deliver the substance to the local public health agency or to local law enforcement.
- SB 519 (Wiener) of 2022 was substantially similar to SB 58. SB 519 died on the Assembly inactive file.
- SB 57 (Wiener) of 2022 would have authorized the City and County of San Francisco, the County of Los Angeles, and the City of Oakland to approve entities to operate overdose prevention program for adults supervised by healthcare professionals or other trained staff where people who use drugs can safely consume drugs and get access or referrals SUD treatment services, primary medical care, mental health services, and social services. SB 57 was vetoed by Governor Newsom whose veto message stated in part:
“I have long supported the cutting edge of harm reduction strategies. However, I am acutely concerned about the operations of safe injection sites without strong, engaged local leadership and well-documented, vetted, and thoughtful operational and sustainability plans. The unlimited number of safe injection sites that this bill would authorize - facilities which could exist well into the later part of this decade - could induce a world of unintended consequences. It is possible that these sites would help improve the safety and health of our urban areas, but if done without a strong plan, they could work against this purpose. These unintended consequences in cities like Los Angeles, San Francisco, and Oakland cannot be taken lightly. Worsening drug consumption challenges in these areas is not a risk we can take.”
- AB 362 (Eggman) of 2020 would have authorized the City and County of San Francisco to approve entities to operate an overdose prevention program for adults supervised by healthcare professionals or other trained staff where people who use drugs can safely consume drugs and get access to referrals to addiction treatment. AB 362 was never heard in the Senate Health Committee.
- AB 2495 (Eggman) of 2016 would have decriminalized conduct connected to use and operation of an adult public health or medical intervention facility that is permitted by state or local health departments and intended to reduce death, disability, or injury due to the use of controlled substances. SB 2495 was heard for testimony in the Assembly Public Safety Committee and returned to the desk.
- PUBLIC HEALTH CONSIDERATIONS.
- Risk and Benefit Assessment. This bill, following state adoption of a framework governing the use, would authorize the therapeutic use of hallucinogenic substances that have not been subjected to the rigorous drug approval process of the FDA. Typically, prior to consumers’ access and consumption of most drugs, particularly when used for therapies for certain conditions, these drugs have gone through the FDA drug approval process. The reverse order of this bill, legalization before FDA approval, could place individuals at unknown risk of harm. Additionally, it establishes a precedent for future drug decriminalization and provides an avenue for factors other than rigorous, science based research, to influence decisions regarding the safety and availability of drugs in California. The assessment for public health determinations should always be whether the benefits of allowing the therapeutic use of the hallucinogenics outweigh the known and potential risks for the intended population.
- Oversight of Research on Scheduled Substances in California. Current law [HSC §11480 & §11481] requires that proposed research studies using certain opioid, stimulant, and hallucinogenic drugs classified as Schedule I and Schedule II Controlled Substances as their main study drug(s), are to be reviewed and authorized by the Research Advisory Panel of California (Panel) within the Attorney General's Office. The Panel primarily seeks to ensure the safety and protection of participating human research subjects and adequate security of the controlled substances are used in the study. The Panel evaluates the scientific validity of each proposed project, and may reject proposals where the research is poorly conceived, would produce conclusions of little scientific value, or would not justify the exposure of California subjects to the risk of research. It is unclear whether decriminalizing the hallucinogenics specified in this bill would remove them from the only existing oversight of research involving these substances in California.
REGISTERED SUPPORT / OPPOSITION:
Support
None on file.
Opposition
None on file.
Analysis Prepared by: Lara Flynn / HEALTH / (916) 319-2097
Discussed in Hearing
View Older HearingsBill Author
Bill Co-Author(s):